Improved detection of recurrent bladder cancer using the bard bta stat test
Abstract To evaluate the BTA stat Test in the detection of recurrent bladder cancer. Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder can...
Saved in:
Published in | Urology (Ridgewood, N.J.) Vol. 50; no. 3; pp. 349 - 353 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.09.1997
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
To evaluate the BTA stat Test in the detection of recurrent bladder cancer.
Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer.
The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers.
The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer. |
---|---|
AbstractList | Abstract
To evaluate the BTA stat Test in the detection of recurrent bladder cancer.
Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer.
The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers.
The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer. To evaluate the BTA stat Test in the detection of recurrent bladder cancer. Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer. The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers. The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer. OBJECTIVESTo evaluate the BTA stat Test in the detection of recurrent bladder cancer.METHODSSensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer.RESULTSThe BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers.CONCLUSIONSThe BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer. |
Author | Henderson, Mary Blumenstein, Brent A. Schervish, Ed W. Pfalzgraf, Randy D. Sarosdy, Michael F. Chodak, Gerald W. Johnson, Robert D. Schellhammer, Paul F. Soloway, Mark S. Adams, George Brunelle, Sharon L. Sheinfeld, Joel White, Ralph deVere Jarowenko, Mark V. Murchison, Heather A. Ellis, William J. Lamm, Donald L. Thoelke, Kent R. Hudson, M'Liss A. Patel, Jay V. |
Author_xml | – sequence: 1 givenname: Michael F. surname: Sarosdy fullname: Sarosdy, Michael F. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 2 givenname: M'Liss A. surname: Hudson fullname: Hudson, M'Liss A. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 3 givenname: William J. surname: Ellis fullname: Ellis, William J. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 4 givenname: Mark S. surname: Soloway fullname: Soloway, Mark S. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 5 givenname: Ralph deVere surname: White fullname: White, Ralph deVere organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 6 givenname: Joel surname: Sheinfeld fullname: Sheinfeld, Joel organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 7 givenname: Mark V. surname: Jarowenko fullname: Jarowenko, Mark V. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 8 givenname: Paul F. surname: Schellhammer fullname: Schellhammer, Paul F. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 9 givenname: Ed W. surname: Schervish fullname: Schervish, Ed W. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 10 givenname: Jay V. surname: Patel fullname: Patel, Jay V. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 11 givenname: Gerald W. surname: Chodak fullname: Chodak, Gerald W. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 12 givenname: Donald L. surname: Lamm fullname: Lamm, Donald L. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 13 givenname: Robert D. surname: Johnson fullname: Johnson, Robert D. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 14 givenname: Mary surname: Henderson fullname: Henderson, Mary organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 15 givenname: George surname: Adams fullname: Adams, George organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 16 givenname: Brent A. surname: Blumenstein fullname: Blumenstein, Brent A. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 17 givenname: Kent R. surname: Thoelke fullname: Thoelke, Kent R. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 18 givenname: Randy D. surname: Pfalzgraf fullname: Pfalzgraf, Randy D. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 19 givenname: Heather A. surname: Murchison fullname: Murchison, Heather A. organization: The University of Texas Health Science Center, San Antonio, Texas, USA – sequence: 20 givenname: Sharon L. surname: Brunelle fullname: Brunelle, Sharon L. organization: The University of Texas Health Science Center, San Antonio, Texas, USA |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2826266$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9301696$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkE1PAyEQhonR1Fr9CU04GKOHVRa6sJyMMX40mniwd8LCoJjtbgW2if9eaptePc1hnpl55zlBh13fAULTklyXpOQ374RIUsyorC6luCKESlrwAzQuKyoKKWV1iMZ75BidxPhFCOGcixEaSZZXSD5GL_PlKvRrsNhCApN83-He4QBmCAG6hJtWWwsBG92ZXIbouw-cPgE3OljcJI1j0gkniOkUHTndRjjb1QlaPD4s7p-L17en-f3da2FYLVNRU1kbbhpDaucY0064snKcEVJVwogZ4Zq6nDl_JKh2ljbGNYzXDWUgZjWboIvt2hz8e8h31dJHA22rO-iHqISksmSMZLDagib0MQZwahX8UocfVRK1caj-HKqNICWF-nOoeJ6b7g4MzRLsfmonLffPd30djW5dyGp83GO0ppzyDXa7xSC7WHsIKhoP2aL1WW9Stvf_BPkFMgCO5Q |
CODEN | URGYAZ |
CitedBy_id | crossref_primary_10_1016_S0022_5347_05_65521_8 crossref_primary_10_1038_modpathol_3800262 crossref_primary_10_1016_j_ucl_2013_01_015 crossref_primary_10_1016_j_urolonc_2023_06_013 crossref_primary_10_1016_S0090_4295_00_00489_1 crossref_primary_10_1016_j_cancergencyto_2005_06_006 crossref_primary_10_1016_S0022_5347_05_67797_X crossref_primary_10_1097_00005392_199902000_00004 crossref_primary_10_2217_17520363_2_2_165 crossref_primary_10_3810_pgm_1999_11_774 crossref_primary_10_2217_bmm_09_23 crossref_primary_10_1074_jbc_275_17_12917 crossref_primary_10_1016_S0090_4295_00_01055_4 crossref_primary_10_1097_00005392_200208000_00013 crossref_primary_10_1002_dc_21831 crossref_primary_10_1373_clinchem_2004_042192 crossref_primary_10_1007_s00120_009_2077_2 crossref_primary_10_1097_00005392_200006000_00013 crossref_primary_10_1016_j_urology_2003_12_004 crossref_primary_10_1002_ctd2_176 crossref_primary_10_1016_j_urolonc_2020_08_016 crossref_primary_10_1016_S0094_0143_05_70051_3 crossref_primary_10_1080_003655999750015835 crossref_primary_10_1097_00005392_200203000_00025 crossref_primary_10_1097_00130747_200205000_00004 crossref_primary_10_1016_S0022_5347_01_61918_9 crossref_primary_10_1016_S0094_0143_05_70055_0 crossref_primary_10_1016_S0022_5347_05_64270_X crossref_primary_10_1016_S1525_1578_10_60625_3 crossref_primary_10_1111_j_1464_410X_2008_07789_x crossref_primary_10_1016_S0009_8981_01_00800_2 crossref_primary_10_1002__SICI_1097_0142_19990215_85_4_919__AID_CNCR21_3_0_CO_2_I crossref_primary_10_1097_00005392_200109000_00010 crossref_primary_10_1016_S0090_4295_01_01307_3 crossref_primary_10_1007_BF01901609 crossref_primary_10_2217_fon_09_57 crossref_primary_10_1046_j_1464_410x_2000_00676_x crossref_primary_10_1097_00005392_199902000_00023 crossref_primary_10_1097_00005392_200102000_00081 crossref_primary_10_1097_00005392_199907000_00014 crossref_primary_10_1016_S0009_8981_00_00246_1 crossref_primary_10_1016_S0022_5347_05_68934_3 crossref_primary_10_1002_pmic_201500164 crossref_primary_10_12968_hosp_2003_64_1_1844 crossref_primary_10_1111_j_1464_410X_2007_07183_x crossref_primary_10_1016_S0090_4295_02_02136_2 crossref_primary_10_1007_s11934_018_0857_1 crossref_primary_10_1016_S0022_5347_05_66080_6 crossref_primary_10_1002_tre_760 crossref_primary_10_1016_j_urolonc_2013_06_001 crossref_primary_10_1016_S0022_5347_01_61899_8 crossref_primary_10_1373_clinchem_2009_133124 crossref_primary_10_1016_j_urolonc_2005_11_023 crossref_primary_10_1016_S1078_1439_99_00002_2 crossref_primary_10_1097_01_LAB_0000074893_70675_2E crossref_primary_10_1016_j_dmpk_2022_100472 crossref_primary_10_1016_S1166_7087_07_92221_6 crossref_primary_10_3390_diagnostics10090612 crossref_primary_10_1016_S0090_4295_02_01672_2 crossref_primary_10_1177_172460080802300409 crossref_primary_10_1016_j_cancergencyto_2009_12_017 crossref_primary_10_4111_icu_20210194 crossref_primary_10_1097_00005392_200102000_00005 crossref_primary_10_1002_cncr_21712 crossref_primary_10_1016_S0022_5347_05_65848_X crossref_primary_10_1586_14737159_7_1_11 crossref_primary_10_1093_jnci_93_6_427 crossref_primary_10_1159_000369357 crossref_primary_10_1093_clinchem_46_5_595 crossref_primary_10_1007_s00120_008_1675_8 crossref_primary_10_1016_S0022_5347_05_65290_1 crossref_primary_10_1007_s00345_018_2380_x crossref_primary_10_1016_S0022_5347_05_67104_2 crossref_primary_10_1016_S0022_5347_01_62747_2 crossref_primary_10_1016_S0923_2532_98_80026_4 crossref_primary_10_1016_S1078_1439_99_00052_6 crossref_primary_10_1097_00005392_200112000_00027 crossref_primary_10_1038_modpathol_2008_193 crossref_primary_10_1016_S0002_9440_10_64100_4 crossref_primary_10_1016_j_cccn_2003_11_008 crossref_primary_10_3389_fonc_2020_01774 crossref_primary_10_3389_fsurg_2021_735868 crossref_primary_10_1111_j_1939_165X_1999_tb01039_x crossref_primary_10_1016_S0360_3016_98_00380_0 crossref_primary_10_1097_00005392_200107000_00018 crossref_primary_10_1002_1097_0142_20010815_92_4_768__AID_CNCR1381_3_0_CO_2_C crossref_primary_10_1016_S0090_4295_02_02073_3 crossref_primary_10_1016_S0210_4806_03_72888_5 crossref_primary_10_1002_cncy_20016 crossref_primary_10_3892_or_2013_2525 crossref_primary_10_1007_s00345_007_0230_3 crossref_primary_10_1016_S0022_5347_05_65072_0 crossref_primary_10_1097_00005392_199905000_00019 crossref_primary_10_4111_kju_2009_50_8_739 crossref_primary_10_1016_S0090_4295_00_00664_6 crossref_primary_10_1080_21681805_2017_1313309 crossref_primary_10_3390_life12030395 crossref_primary_10_1016_S0022_5347_05_65965_4 crossref_primary_10_1080_00032710008543210 crossref_primary_10_1016_S0090_4295_00_01090_6 crossref_primary_10_1097_00005392_200011000_00099 crossref_primary_10_1016_S0022_5347_01_68168_0 crossref_primary_10_1016_j_urology_2005_08_034 crossref_primary_10_1016_S0302_2838_01_00015_X crossref_primary_10_5483_BMBRep_2003_36_4_399 crossref_primary_10_1002_cncy_21264 crossref_primary_10_1016_S0090_4295_99_00383_0 crossref_primary_10_1016_S0022_5347_05_64659_9 crossref_primary_10_1016_S0022_5347_01_63060_X crossref_primary_10_1016_S0022_5347_05_67521_0 crossref_primary_10_1016_S1570_9124_03_00022_9 crossref_primary_10_1007_s00120_006_1065_z crossref_primary_10_1016_S0094_0143_05_70239_1 crossref_primary_10_1016_S0094_0143_05_70235_4 crossref_primary_10_1097_00005392_200211000_00013 crossref_primary_10_1016_S0210_4806_06_73394_0 crossref_primary_10_1097_00005392_200205000_00015 crossref_primary_10_1177_172460080001500303 crossref_primary_10_1097_00005392_200003000_00012 crossref_primary_10_1517_17530050902824811 crossref_primary_10_1200_JCO_2006_08_0895 crossref_primary_10_1016_S0009_8981_03_00074_3 crossref_primary_10_1007_s11864_004_0028_0 crossref_primary_10_1016_S0022_5347_05_68050_0 crossref_primary_10_1097_00005392_199809010_00003 crossref_primary_10_1097_00005392_199807000_00054 crossref_primary_10_1586_era_12_50 |
Cites_doi | 10.1016/S0022-5347(01)67054-X 10.1016/S0022-5347(17)49814-4 10.1016/S0022-5347(01)65851-8 10.3322/canjclin.38.4.213 10.1080/03610918008812161 10.1016/S0022-5347(01)66422-X |
ContentType | Journal Article |
Copyright | 1997 Elsevier Science Inc. 1997 INIST-CNRS |
Copyright_xml | – notice: 1997 Elsevier Science Inc. – notice: 1997 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/S0090-4295(97)00292-6 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1527-9995 |
EndPage | 353 |
ExternalDocumentID | 10_1016_S0090_4295_97_00292_6 9301696 2826266 S0090429597002926 |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M -RU .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAEJM AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABLJU ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACIUM ACRLP ACRZS ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJJEV AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQVPL ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HZ~ IHE J1W KOM L7B LCYCR LZ2 M29 M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSZ T5K UV1 WH7 WOW WUQ X7M XPP Z5R ZA5 ZGI ~G- 08R AAPBV AAUGY ABPIF ABPTK IQODW AAXKI AFJKZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c389t-8298c6cbc08ff33af7f15f6300557c7406a2f29502972afd2bcfb368b23e7483 |
IEDL.DBID | .~1 |
ISSN | 0090-4295 |
IngestDate | Fri Oct 25 01:52:46 EDT 2024 Thu Sep 26 19:39:51 EDT 2024 Sat Sep 28 08:35:30 EDT 2024 Sun Oct 29 17:08:45 EDT 2023 Sat Apr 06 16:24:42 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Human Urine Relapse Urinary system disease Immunoaffinity chromatography Cytologic investigation Colorimetry Urinary tract disease Malignant tumor Medical screening Sensitivity Specificity Urinary bladder Bladder disease |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c389t-8298c6cbc08ff33af7f15f6300557c7406a2f29502972afd2bcfb368b23e7483 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 9301696 |
PQID | 79291330 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_79291330 crossref_primary_10_1016_S0090_4295_97_00292_6 pubmed_primary_9301696 pascalfrancis_primary_2826266 elsevier_sciencedirect_doi_10_1016_S0090_4295_97_00292_6 |
PublicationCentury | 1900 |
PublicationDate | 1997-09-01 |
PublicationDateYYYYMMDD | 1997-09-01 |
PublicationDate_xml | – month: 09 year: 1997 text: 1997-09-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Urology (Ridgewood, N.J.) |
PublicationTitleAlternate | Urology |
PublicationYear | 1997 |
Publisher | Elsevier Inc Elsevier Science |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Science |
References | Whitmore (bib1) 1988; 38 Leyh, Marberger, Pagano, Bassi, Sternberg, Pansadoro, Conort, Boccon-Gibod, Thoelke (bib9) 1997; 157 (bib3) 1977; 37 Schork, Williams (bib15) 1980; 139 Mostofi (bib14) 1973 Sarosdy, deVere White, Soloway, Sheinfeld, Hudson, Schellhammer, Jarowenko, Adams, Blumenstein (bib5) 1995; 154 Kinders, Root, Jones, Bruce, Hass (bib11) 1997; 38 Mostofi, Davis, Sesterhenn (bib2) 1988 D'Hallewin, Baert (bib6) 1996; 155 Soloway, Briggman, Carpinito, Chodak, Church, Lamm, Lange, Messing, Pasciak, Reservitz (bib16) 1996; 156 Fradet, Cordon-Cardo (bib17) 1993; 11 Zein, Wajsman, Englander, Gamarra, Lopez, Huben, Pontes (bib4) 1984; 132 Leyh, Mazeman, Hall, Bennett (bib7) 1996; 155 Austyn, Wood (bib12) 1993 Kinders, Jones, Root, Murchison, Bruce, Williams, Hass (bib10) 1997; 157 Brunelle, Kinders, Murchison, Pfalzgraf, Root (bib8) July 1996 American Joint Committee on Cancer (bib13) 1988 Austyn (10.1016/S0090-4295(97)00292-6_bib12) 1993 Soloway (10.1016/S0090-4295(97)00292-6_bib16) 1996; 156 Leyh (10.1016/S0090-4295(97)00292-6_bib9) 1997; 157 Kinders (10.1016/S0090-4295(97)00292-6_bib11) 1997; 38 Kinders (10.1016/S0090-4295(97)00292-6_bib10) 1997; 157 Mostofi (10.1016/S0090-4295(97)00292-6_bib2) 1988 Sarosdy (10.1016/S0090-4295(97)00292-6_bib5) 1995; 154 Fradet (10.1016/S0090-4295(97)00292-6_bib17) 1993; 11 D'Hallewin (10.1016/S0090-4295(97)00292-6_bib6) 1996; 155 Schork (10.1016/S0090-4295(97)00292-6_bib15) 1980; 139 Brunelle (10.1016/S0090-4295(97)00292-6_bib8) 1996 American Joint Committee on Cancer (10.1016/S0090-4295(97)00292-6_bib13) 1988 Mostofi (10.1016/S0090-4295(97)00292-6_bib14) 1973 Zein (10.1016/S0090-4295(97)00292-6_bib4) 1984; 132 Leyh (10.1016/S0090-4295(97)00292-6_bib7) 1996; 155 (10.1016/S0090-4295(97)00292-6_bib3) 1977; 37 Whitmore (10.1016/S0090-4295(97)00292-6_bib1) 1988; 38 |
References_xml | – year: 1973 ident: bib14 article-title: Histological Typing of Urinary Bladder Tumors. International Histological Classification of Tumours contributor: fullname: Mostofi – volume: 139 start-page: 349 year: 1980 end-page: 358 ident: bib15 article-title: Number of observations required for the comparison of two correlated proportions publication-title: Commun Statistical Simulation Computation contributor: fullname: Williams – volume: 155 start-page: 475 year: 1996 end-page: 476 ident: bib6 article-title: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer publication-title: J Urol contributor: fullname: Baert – volume: 157 start-page: 337A year: 1997 ident: bib9 article-title: Results of a European multicenter trial comparing the BTA publication-title: J Urol contributor: fullname: Thoelke – volume: 37 start-page: 2911 year: 1977 end-page: 2915 ident: bib3 article-title: Cytology and histopathology of bladder cancer cases in a prospective longitudinal study publication-title: Cancer Res – volume: 132 start-page: 670 year: 1984 end-page: 671 ident: bib4 article-title: Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa publication-title: J Urol contributor: fullname: Pontes – start-page: 194 year: 1988 end-page: 224 ident: bib13 publication-title: Manual for Staging of Cancer contributor: fullname: American Joint Committee on Cancer – start-page: 522 year: 1993 end-page: 554 ident: bib12 article-title: Principles of Cellular and Molecular Immunology contributor: fullname: Wood – volume: 154 start-page: 379 year: 1995 end-page: 384 ident: bib5 article-title: Results of a multicenter trial using the BTA Test to monitor for and diagnose recurrent bladder cancer publication-title: J Urol contributor: fullname: Blumenstein – year: July 1996 ident: bib8 article-title: Rapid detection of bladder tumor antigen in urine with the Bard BTA publication-title: International Congress of Clinical Chemistry contributor: fullname: Root – volume: 156 start-page: 363 year: 1996 end-page: 367 ident: bib16 article-title: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment publication-title: J Urol contributor: fullname: Reservitz – volume: 157 start-page: 28A year: 1997 ident: bib10 article-title: Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family publication-title: J Urol contributor: fullname: Hass – volume: 11 start-page: 145 year: 1993 end-page: 153 ident: bib17 article-title: Critical appraisal of tumor markers in bladder cancer publication-title: Semin Urol contributor: fullname: Cordon-Cardo – volume: 38 start-page: 29A year: 1997 ident: bib11 article-title: Complement factor H-related proteins are expressed in bladder cancers publication-title: Cancer Res contributor: fullname: Hass – volume: 155 start-page: 492A year: 1996 ident: bib7 article-title: Results of a European multicenter trial comparing the Bard BTA Test to urine cytology in patients suspected of having bladder cancer publication-title: J Urol contributor: fullname: Bennett – volume: 38 start-page: 213 year: 1988 end-page: 223 ident: bib1 article-title: Bladder cancer: an overview publication-title: CA Cancer J Clin contributor: fullname: Whitmore – start-page: 83 year: 1988 end-page: 113 ident: bib2 article-title: Pathology of tumors of the urinary tract publication-title: Diagnosis and Management of Genitourinary Cancer contributor: fullname: Sesterhenn – start-page: 522 year: 1993 ident: 10.1016/S0090-4295(97)00292-6_bib12 article-title: Principles of Cellular and Molecular Immunology contributor: fullname: Austyn – year: 1973 ident: 10.1016/S0090-4295(97)00292-6_bib14 contributor: fullname: Mostofi – volume: 154 start-page: 379 year: 1995 ident: 10.1016/S0090-4295(97)00292-6_bib5 article-title: Results of a multicenter trial using the BTA Test to monitor for and diagnose recurrent bladder cancer publication-title: J Urol doi: 10.1016/S0022-5347(01)67054-X contributor: fullname: Sarosdy – volume: 132 start-page: 670 year: 1984 ident: 10.1016/S0090-4295(97)00292-6_bib4 article-title: Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa publication-title: J Urol doi: 10.1016/S0022-5347(17)49814-4 contributor: fullname: Zein – volume: 156 start-page: 363 year: 1996 ident: 10.1016/S0090-4295(97)00292-6_bib16 article-title: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment publication-title: J Urol doi: 10.1016/S0022-5347(01)65851-8 contributor: fullname: Soloway – year: 1996 ident: 10.1016/S0090-4295(97)00292-6_bib8 article-title: Rapid detection of bladder tumor antigen in urine with the Bard BTA stat Assay contributor: fullname: Brunelle – start-page: 194 year: 1988 ident: 10.1016/S0090-4295(97)00292-6_bib13 contributor: fullname: American Joint Committee on Cancer – volume: 11 start-page: 145 year: 1993 ident: 10.1016/S0090-4295(97)00292-6_bib17 article-title: Critical appraisal of tumor markers in bladder cancer publication-title: Semin Urol contributor: fullname: Fradet – volume: 38 start-page: 29A year: 1997 ident: 10.1016/S0090-4295(97)00292-6_bib11 article-title: Complement factor H-related proteins are expressed in bladder cancers publication-title: Cancer Res contributor: fullname: Kinders – volume: 38 start-page: 213 year: 1988 ident: 10.1016/S0090-4295(97)00292-6_bib1 article-title: Bladder cancer: an overview publication-title: CA Cancer J Clin doi: 10.3322/canjclin.38.4.213 contributor: fullname: Whitmore – volume: 37 start-page: 2911 year: 1977 ident: 10.1016/S0090-4295(97)00292-6_bib3 article-title: Cytology and histopathology of bladder cancer cases in a prospective longitudinal study publication-title: Cancer Res – start-page: 83 year: 1988 ident: 10.1016/S0090-4295(97)00292-6_bib2 article-title: Pathology of tumors of the urinary tract contributor: fullname: Mostofi – volume: 155 start-page: 492A year: 1996 ident: 10.1016/S0090-4295(97)00292-6_bib7 article-title: Results of a European multicenter trial comparing the Bard BTA Test to urine cytology in patients suspected of having bladder cancer publication-title: J Urol contributor: fullname: Leyh – volume: 157 start-page: 28A year: 1997 ident: 10.1016/S0090-4295(97)00292-6_bib10 article-title: Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family publication-title: J Urol contributor: fullname: Kinders – volume: 139 start-page: 349 year: 1980 ident: 10.1016/S0090-4295(97)00292-6_bib15 article-title: Number of observations required for the comparison of two correlated proportions publication-title: Commun Statistical Simulation Computation doi: 10.1080/03610918008812161 contributor: fullname: Schork – volume: 155 start-page: 475 year: 1996 ident: 10.1016/S0090-4295(97)00292-6_bib6 article-title: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer publication-title: J Urol doi: 10.1016/S0022-5347(01)66422-X contributor: fullname: D'Hallewin – volume: 157 start-page: 337A year: 1997 ident: 10.1016/S0090-4295(97)00292-6_bib9 article-title: Results of a European multicenter trial comparing the BTA stat Test to urine cytology in patients suspected of having bladder cancer publication-title: J Urol contributor: fullname: Leyh |
SSID | ssj0006667 |
Score | 2.0033486 |
Snippet | Abstract
To evaluate the BTA stat Test in the detection of recurrent bladder cancer.
Sensitivity and specificity were determined using frozen voided urine... To evaluate the BTA stat Test in the detection of recurrent bladder cancer. Sensitivity and specificity were determined using frozen voided urine samples from... OBJECTIVESTo evaluate the BTA stat Test in the detection of recurrent bladder cancer.METHODSSensitivity and specificity were determined using frozen voided... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 349 |
SubjectTerms | Aged Aged, 80 and over Antigens, Neoplasm - urine Biological and medical sciences Female Humans Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - urine Neoplasm Staging Nephrology. Urinary tract diseases Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Sensitivity and Specificity Tumors of the urinary system Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - urine Urinary system Urinary tract. Prostate gland |
Title | Improved detection of recurrent bladder cancer using the bard bta stat test |
URI | https://dx.doi.org/10.1016/S0090-4295(97)00292-6 https://www.ncbi.nlm.nih.gov/pubmed/9301696 https://search.proquest.com/docview/79291330 |
Volume | 50 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA6lgggiPrE-ag4e9JC2-0qyx1Is1dKeFLyFJJuIINvSbq_-dmd2ty09iOA1u8lmZ5KZbzKPEHLvvTYWcAITxocsToOEwS4yzCWZ8zYLHLeYKDyZ8tFb_PKevDfIYJ0Lg2GVteyvZHopreuWbk3N7vzzE3N8U5SmgIjRtRRi2e0Y1B-s6c73NswD4HldN7PH8O1tFk81Qtn4kIrHchDGf9NPh3O9BKr56rqL3_FoqZeGx-SoBpS0X835hDRcfkr2J7XL_IyMq2MDl9HMFWXcVU5nni7wnB0rM1HzhcJnQS3yf0ExEP6DAiykBhYPNYWmmHREAZIW5-R1-PQ6GLH6BgVmAYgUTIaptNwa25PeR5H2wgeJxypbSSKsAGWuQw__jzdYhdpnobHeRFyaMHIiltEFaeaz3F0S2gtkFnOttUWDLQi0SD3nxgshUykD2yKdNdnUvKqTobYBZEBnhXRWpbcb6Kx4i8g1cdUOwxXI8r-63u4wY_NBMB_BPoPnd2vmKNgs6AHRuZutlkoAGASjvNciFxXPNl3TCMvS8Kv_z-qaHFSlbTH-7IY0i8XK3QJgKUy7XJFtstd_Ho-mP2Aa5Vk |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFH_4ASqI-InzMwcPeoiu7ZqkRxFlOrfTBG8hSRMZSDdm_f99r-02PAzBa0vS9L3kl9_L-wjAVQjGOuQJXNoQ804WpRxXkeU-zX1weeSFo0Th_kB03zov7-n7CjzMcmEorLLB_hrTK7Runtw10rybjEaU45sRmiIjJtdSLFZhHdlAhqtz_f651x3MARkZelM6s82pwSKRp-6kenidyZuqHy6WbVHbE_OFggv1jRfLKWm1NT3twk7DKdl9Pew9WPHFPmz0G6_5AfTqkwOfs9yXVehVwcaBTemonYozMftJ-DNljqbAlFEs_AdDZsgszh9mS8Mo74ghKy0PYfj0OHzo8uYSBe6Qi5RcxZlywlnXViEkiQkyRGmgQltpKp3E_dzEAf-fLrGKTchj64JNhLJx4mVHJUewVowLfwysHam8I4wxjmy2KDIyC0LYIKXKlIpcC25nYtOTulSGXsSQoZw1yVlXDm-UsxYtUDPh6l861wjnfzU9_6WM-QfRgkQTDd9fzpSjcb2QE8QUfvz9pSXyQbTL2y04qnU2b5olVJlGnPx_VJew2R32X_Xr86B3Clt1pVsKRzuDtXL67c-Rv5T2opmfP1q36A0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+detection+of+recurrent+bladder+cancer+using+the+bard+BTA+stat+test&rft.jtitle=Urology+%28Ridgewood%2C+N.J.%29&rft.au=SAROSDY%2C+M.+F&rft.au=HUDSON%2C+M.+A&rft.au=CHODAK%2C+G.+W&rft.au=LAMM%2C+D.+L&rft.date=1997-09-01&rft.pub=Elsevier+Science&rft.issn=0090-4295&rft.eissn=1527-9995&rft.volume=50&rft.issue=3&rft.spage=349&rft.epage=353&rft_id=info:doi/10.1016%2FS0090-4295%2897%2900292-6&rft.externalDBID=n%2Fa&rft.externalDocID=2826266 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-4295&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-4295&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-4295&client=summon |